Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

Chevron's dividend yield is more than three times higher than the S&P 500. The oil giant has increased its dividend each year for nearly four decades. It has plenty of fuel to continue growing its ...

Jeremy has more than 2300 published articles on Collider to his name, and has been writing for the site since February 2022. He's an omnivore when it comes to his movie-watching diet, so will gladly ...

Ashely Claudino is an Evergreen Staff Writer from Portugal. She has a Translation degree from the University of Lisbon (2020, Faculty of Arts and Humanities). She has been writing for Game Rant since ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...

Generate Biomedicines Inc. filed for an initial public offering, joining a growing list of biotechnology firms to leap to public markets as investors embrace the sector. The Somerville, ...

With the college football transfer portal window set to close Friday, there are still some intriguing late entrants making moves for their future. A notable entry into the portal from the Division II ...

Not the hill I'd die on, but I'm not a billionaire. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.